UK weight-loss drug demand up as NHS tightens access and prices rise

Demand for weight loss medications in the United Kingdom has surged again in 2025, with roughly 1.5 million people now using such drugs and about half of them on Mounjaro or its main rival Wegovy. The situation comes as the NHS began offering Mounjaro through its system for those with the greatest clinical need, while the drug’s price for private patients is set to rise sharply from September. The combination of rising demand, carefully targeted NHS access, and a major price adjustment for private purchases is intensifying the already crowded landscape for obesity treatment in the UK.

Healthcare policymakers point to a sustained rise in obesity and overweight prevalence as the backdrop to these developments. England reported that about two in three adults were overweight or obese in the 2022–2023 period, underscoring a large patient base for therapies that can aid weight management when paired with diet and exercise. Mounjaro, whose active ingredient is tirzepatide, works by activating two hormone receptors that regulate appetite and insulin production, helping users feel fuller sooner and slow the passage of food through the digestive system. The drug was approved for obesity...